100+ datasets found
  1. L

    HIV Drugs Market

    • transparencymarketresearch.com
    csv, pdf
    Updated Jun 19, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Transparency Market Research (2024). HIV Drugs Market [Dataset]. https://www.transparencymarketresearch.com/hiv-drugs-market.html
    Explore at:
    csv, pdfAvailable download formats
    Dataset updated
    Jun 19, 2024
    Dataset authored and provided by
    Transparency Market Research
    License

    https://www.transparencymarketresearch.com/privacy-policy.htmlhttps://www.transparencymarketresearch.com/privacy-policy.html

    Time period covered
    2024 - 2034
    Area covered
    Worldwide
    Description

    • The global industry was valued at US$ 28.6 Bn in 2023
    • It is expected to grow at a CAGR of 4.7% from 2024 to 2034 and reach US$ 47.5 Bn by the end of 2034

    HIV Drugs Market Overview

    AttributeDetail
    Market Drivers
    • Growing Prevalence of HIV Infections
    • Growing Emphasis on R&D related to HIV Drugs

    Regional Analysis

    AttributeDetail
    Leading RegionNorth America

    Global HIV Drugs Market Snapshot

    AttributeDetail
    Market Size in 2023US$ 28.6 Bn
    Market Forecast (Value) in 2034US$ 47.5 Bn
    Growth Rate (CAGR)4.7%
    Forecast Period2024-2034
    Historical Data Available for2020-2022
    Quantitative UnitsUS$ Bn for Value
    Market AnalysisIt includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
    Competition Landscape
    • Market share analysis by company (2023)
    • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
    FormatElectronic (PDF) + Excel
    Market Segmentation
    • Drug Type
      • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
      • Protease Inhibitors (PIs)
      • Fusion Inhibitors (FIs)
      • C-C Chemokine Receptor Type 5 (CCR5)
      • Integrase Inhibitors
      • Attachment Inhibitors
      • Post Attachment Inhibitors
      • Pharmacokinetic Enhancers
      • Post-Exposure Prophylaxis (PEP)
      • Pre-Exposure Prophylaxis (PrEP)
      • Others (Combination HIV Medications, etc.)
    • Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    Regions Covered
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
    Countries Covered
    • U.S.
    • Canada
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Brazil
    • Mexico
    • South Africa
    • GCC
    Companies Profiled
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Johnson & Johnson
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • GSK plc
    • AbbVie Inc.
    • Cipla Limited
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    Customization ScopeAvailable Upon Request
    PricingAvailable Upon Request

  2. Top HIV/AIDS drugs worldwide based on revenue 2023

    • statista.com
    Updated May 21, 2024
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2024). Top HIV/AIDS drugs worldwide based on revenue 2023 [Dataset]. https://www.statista.com/statistics/273434/revenue-of-the-worlds-most-important-aids-drugs/
    Explore at:
    Dataset updated
    May 21, 2024
    Dataset authored and provided by
    Statistahttp://statista.com/
    Time period covered
    2023
    Area covered
    Worldwide
    Description

    Globally, over many years, one of the top drugs for the treatment of HIV/AIDS is Genvoya, marketed by Gilead. In 2023, Genvoya generated some two billion U.S. dollars in revenue. Biktarvy, also marketed by Gilead, was the best-selling HIV/AIDS treatment and generated around 11.9 billion U.S. dollars in revenue. Gilead is the drug manufacturer most specialized in developing drugs for the treatment of HIV/AIDS.

    HIV/AIDS cases worldwide

    HIV is a virus that attacks the immune system, leading to an increased risk of infections and can lead to death. HIV/AIDS first appeared in global populations in the 1980s. According to current estimates, the prevalence of HIV is highest in low and middle income countries. Eswatini, followed by Lesotho, had the highest rates of HIV infections in 2022. The number of new HIV infections by world region is highest among residents of Eastern and Southern Africa.

    Access to HIV/AIDS treatment

    Effective treatment for HIV was not available until the early 1990s. Access to therapy has increased since the early 2000s, and as of 2022 there were approximately 30 million people that had access to antiretroviral therapy. Among countries around the world, Uganda, India and Kenya, to name a few, have the lowest rates of access to antiretroviral medications for the treatment of HIV/AIDS. Meanwhile, trends indicate that children living with HIV in Asia or the Pacific have some of the highest rates of access to antiretroviral therapy globally.

  3. c

    The global HIV drugs market size is USD 35425.2 million in 2024.

    • cognitivemarketresearch.com
    pdf,excel,csv,ppt
    Updated May 31, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Cognitive Market Research (2025). The global HIV drugs market size is USD 35425.2 million in 2024. [Dataset]. https://www.cognitivemarketresearch.com/hiv-drugs-market-report
    Explore at:
    pdf,excel,csv,pptAvailable download formats
    Dataset updated
    May 31, 2025
    Dataset authored and provided by
    Cognitive Market Research
    License

    https://www.cognitivemarketresearch.com/privacy-policyhttps://www.cognitivemarketresearch.com/privacy-policy

    Time period covered
    2021 - 2033
    Area covered
    Global
    Description

    According to Cognitive Market Research, the global HIV drugs market size will be USD 35425.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.80% from 2024 to 2031.

    North America held the major market share for more than 40% of the global revenue with a market size of USD 14170.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.
    Europe accounted for a market share of over 30% of the global revenue with a market size of USD 10627.56 million.
    Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 8147.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.
    Latin America had a market share of more than 5% of the global revenue with a market size of USD 1771.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
    Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 708.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.
    The multi-class combination drugs held the highest HIV drugs market revenue share in 2024.
    

    Market Dynamics of HIV drugs Market

    Key Drivers for HIV drugs Market

    Rising number of HIV-positive individuals to Increase the Demand Globally

    The HIV drugs market has experienced growth due to rising number of HIV-positive individuals. As global HIV prevalence increases due to factors like higher transmission rates and improved diagnostic capabilities, demand for effective antiretroviral therapies (ART) surges. This growing patient base necessitates the continuous development and supply of innovative drugs to manage HIV effectively, reduce viral loads, and improve quality of life. Increased awareness and testing also contribute to higher diagnosed cases, further expanding the market for HIV treatments and driving pharmaceutical companies to invest in research and development.

    Innovations in HIV diagnostic tools to Propel Market Growth

    The HIV drugs market has witnessed steady growth, driven by innovations in HIV diagnostic tools. Advances include rapid, point-of-care tests that deliver results within minutes, improving patient access and reducing diagnostic delays. Integrated technologies, such as multiplex assays, detect multiple markers simultaneously, increasing diagnostic accuracy. Additionally, digital platforms for data management streamline monitoring and personalized treatment plans. These innovations not only improve patient outcomes but also stimulate demand for more effective HIV treatments and management solutions, fostering market growth.

    Restraint Factor for the HIV drugs Market

    High cost of HIV treatment to Limit the Sales

    The high costs of HIV medications constrain the growth of HIV drugs market. It involves expensive medications that can be unaffordable for many patients, especially in low-income regions. The costs are compounded by the need for lifelong treatment, regular monitoring, and potential side effects management, which further burdens healthcare systems and patients. This financial barrier limits access to effective treatment, leading to disparities in care and hindering efforts to control the HIV epidemic globally.

    Impact of Covid-19 on the HIV drugs Market

    The Covid-19 significantly impacted the market by disrupting supply chains, leading to delays in drug production and distribution, increasing lockdowns and restrictions. Additionally, the focus on COVID-19 diverted resources away from HIV programs, affecting drug availability and patient adherence. However, the pandemic also accelerated the adoption of telemedicine and digital health solutions, which helped maintain patient care continuity. Overall, the pandemic highlighted the need for resilient healthcare systems in managing chronic diseases. Introduction of the HIV drugs Market

    HIV drugs are medications used to treat Human Immunodeficiency Virus (HIV) infection. They work by suppressing the virus, preventing its replication, and protecting the immune system. These drugs are typically used in combination as antiretroviral therapy (ART) to reduce viral load, improve patient outcomes, and prevent the progression to AIDS. The rising number of HIV-positive individuals, advancemnets in drug development, increasing government initiatives and funding, increased aw...

  4. H

    Prophylactic HIV Drugs Market Growth - Industry Trends & Forecast 2025 to...

    • futuremarketinsights.com
    pdf
    Updated May 15, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Future Market Insights (2025). Prophylactic HIV Drugs Market Growth - Industry Trends & Forecast 2025 to 2035 [Dataset]. https://www.futuremarketinsights.com/reports/prophylactic-hiv-drugs-market
    Explore at:
    pdfAvailable download formats
    Dataset updated
    May 15, 2025
    Dataset authored and provided by
    Future Market Insights
    License

    https://www.futuremarketinsights.com/privacy-policyhttps://www.futuremarketinsights.com/privacy-policy

    Time period covered
    2025 - 2035
    Area covered
    Worldwide
    Description

    The Prophylactic HIV Drugs Market will expand to reach USD 54.7 billion during 2035 from USD 35.2 billion in 2025 due to an anticipated 4.5% CAGR throughout the forecast period.

    MetricValue
    Market Size (2025E)USD 35.2 Billion
    Market Value (2035F)USD 54.7 Billion
    CAGR (2025 to 2035)4.5%

    Country-wise Insights

    CountryCAGR (2025 to 2035)
    United States4.7%
    CountryCAGR (2025 to 2035)
    United Kingdom4.2%
    CountryCAGR (2025 to 2035)
    European Union4.5%
    CountryCAGR (2025 to 2035)
    Japan4.3%
    CountryCAGR (2025 to 2035)
    South Korea4.4%

    Prophylactic HIV Drugs- Segmentation Outlook

    Drug ClassMarket Share
    Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)63.5%
    Distribution ChannelMarket Share
    Hospital Pharmacies45.8%

    Competitive Outlook

    Company NameEstimated Market Share (%)
    Gilead Sciences35-40%
    ViiV Healthcare25-30%
    Merck & Co., Inc.15-20%
    Johnson & Johnson5-10%
    Other Companies (combined)10-15%
  5. A

    Anti-retroviral Drugs Market Report

    • marketreportanalytics.com
    doc, pdf, ppt
    Updated May 1, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Report Analytics (2025). Anti-retroviral Drugs Market Report [Dataset]. https://www.marketreportanalytics.com/reports/anti-retroviral-drugs-market-94054
    Explore at:
    pdf, doc, pptAvailable download formats
    Dataset updated
    May 1, 2025
    Dataset authored and provided by
    Market Report Analytics
    License

    https://www.marketreportanalytics.com/privacy-policyhttps://www.marketreportanalytics.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The global anti-retroviral (ARV) drugs market, valued at approximately $25 billion in 2025, is projected to experience steady growth, exhibiting a compound annual growth rate (CAGR) of 4.00% from 2025 to 2033. This growth is fueled by several key drivers, including the increasing prevalence of HIV/AIDS globally, particularly in developing nations where access to treatment remains a challenge. Ongoing research and development efforts are leading to the introduction of newer, more effective ARV drugs with improved tolerability and reduced side effects, further driving market expansion. The emergence of drug-resistant strains of HIV necessitates the development and adoption of new treatment regimens, presenting both a challenge and an opportunity for pharmaceutical companies. Market segmentation reveals a diverse landscape, with protease inhibitors, integrase inhibitors, and multi-class combination products representing significant segments, reflecting the evolving treatment strategies and the increasing complexity of managing HIV infection. The market's growth, however, faces restraints such as the potential for generic competition and price pressures, especially in price-sensitive markets. The successful implementation of public health initiatives and improved access to affordable ARV drugs in underserved regions will significantly influence the market's future trajectory. The regional distribution of the ARV drug market shows significant variations. North America and Europe are expected to maintain substantial market shares due to high healthcare expenditure and advanced healthcare infrastructure. However, the Asia-Pacific region, particularly countries like India and China, is anticipated to experience significant growth owing to increasing HIV prevalence and rising disposable incomes. The Middle East and Africa, while facing challenges in access to healthcare, also present a significant growth potential given the high prevalence of HIV/AIDS in some regions. Key players in the market, including AbbVie, Gilead Sciences, Merck, and Johnson & Johnson, continue to invest heavily in research and development, seeking to innovate and maintain market leadership through the development of novel therapies and improved treatment approaches. This competitive landscape underscores the importance of strategic partnerships, distribution networks, and pricing strategies for successful market penetration. Recent developments include: In September 2022, Merck reported initiating a new phase 3 clinical trial evaluating once-daily oral islatravir for HIV-1 infection., In August 2022, Gilead received the global regulatory approval of Sunlenca (Lenacapavir), the twice-yearly HIV treatment option.. Key drivers for this market are: Rising Burden of HIV, Increasing Investment in R&D; Increase in Availability of Novel Drugs with Better Efficacy. Potential restraints include: Rising Burden of HIV, Increasing Investment in R&D; Increase in Availability of Novel Drugs with Better Efficacy. Notable trends are: Multi-class Combination Product Segment is Expected to Register a Significant Growth Over the Forecast Period..

  6. G

    Global Antiretroviral Therapy Market Report

    • marketreportanalytics.com
    doc, pdf, ppt
    Updated Jun 20, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Report Analytics (2025). Global Antiretroviral Therapy Market Report [Dataset]. https://www.marketreportanalytics.com/reports/global-antiretroviral-therapy-market-3128
    Explore at:
    pdf, ppt, docAvailable download formats
    Dataset updated
    Jun 20, 2025
    Dataset authored and provided by
    Market Report Analytics
    License

    https://www.marketreportanalytics.com/privacy-policyhttps://www.marketreportanalytics.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The Global Antiretroviral Therapy (ART) Market is valued at approximately $35 billion and is experiencing robust growth, exhibiting a compound annual growth rate (CAGR) of 5%. This expansion is fueled by several key factors. Firstly, the increasing prevalence of HIV/AIDS globally necessitates a sustained demand for effective ART regimens. Secondly, advancements in ART have led to the development of more tolerable and efficacious drugs, improving patient adherence and treatment outcomes. The rising awareness of HIV/AIDS and improved access to diagnostic testing contribute to earlier diagnosis and treatment initiation, further driving market growth. Government initiatives focused on combating the HIV/AIDS epidemic, including increased funding for treatment programs and public awareness campaigns, play a crucial role. Finally, the expansion of ART access to low- and middle-income countries, supported by international organizations and pharmaceutical companies, fuels market expansion in previously underserved populations. The market encompasses various applications, including the treatment of HIV/AIDS, pre-exposure prophylaxis (PrEP) to prevent new infections, and the reduction of HIV transmission risk. Major players like Gilead, ViiV Healthcare, Janssen Pharmaceuticals, and F. Hoffmann-La Roche dominate the market landscape, constantly innovating to improve treatment efficacy and accessibility.

  7. m

    Prophylactic HIV Drugs Market Size & Share Analysis - Industry Research...

    • mordorintelligence.com
    pdf,excel,csv,ppt
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Mordor Intelligence, Prophylactic HIV Drugs Market Size & Share Analysis - Industry Research Report - Growth Trends [Dataset]. https://www.mordorintelligence.com/industry-reports/prophylactic-hiv-drugs-market
    Explore at:
    pdf,excel,csv,pptAvailable download formats
    Dataset authored and provided by
    Mordor Intelligence
    License

    https://www.mordorintelligence.com/privacy-policyhttps://www.mordorintelligence.com/privacy-policy

    Time period covered
    2019 - 2030
    Area covered
    Global
    Description

    The Prophylactic HIV Drugs Market Report is Segmented by Drug (Tenofovir, Emtricitabine, and Other Drugs), Dosage Form (Oral and Topical), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Market Sizes and Forecasts in Terms of Value (USD) for the Above Segments.

  8. Africa HIV Drugs Market Research Report: Forecast (2024-2030)

    • marknteladvisors.com
    Updated May 3, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    MarkNtel Advisors (2024). Africa HIV Drugs Market Research Report: Forecast (2024-2030) [Dataset]. https://www.marknteladvisors.com/research-library/africa-hiv-drugs-market.html
    Explore at:
    Dataset updated
    May 3, 2024
    Dataset authored and provided by
    MarkNtel Advisors
    License

    https://www.marknteladvisors.com/privacy-policyhttps://www.marknteladvisors.com/privacy-policy

    Area covered
    Africa, Global
    Description

    The Africa HIV Drugs Market is projected to expand steadily at a rate of approximately 8.20% CAGR from 2024 to 2030. By Drug Class, By Distribution Channel

  9. R

    Anti-retroviral Protease Inhibitors Market Size Report 2037

    • researchnester.com
    Updated May 29, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Research Nester (2025). Anti-retroviral Protease Inhibitors Market Size Report 2037 [Dataset]. https://www.researchnester.com/reports/antiretroviral-protease-inhibitors-market/2553
    Explore at:
    Dataset updated
    May 29, 2025
    Dataset authored and provided by
    Research Nester
    License

    https://www.researchnester.comhttps://www.researchnester.com

    Description

    The anti-retroviral protease inhibitors market size was valued at USD 3.7 billion in 2024 and is projected to reach USD 7.3 billion by the end of 2037, rising at a CAGR of 7.5 % during the forecast period, i.e., from 2025 to 2037. North America is poised to account for the largest revenue share of 48.8% due to its advanced healthcare infrastructure.

  10. HIV Antivirals Market by Product, Distribution Channel & Region - Forecast...

    • futuremarketinsights.com
    pdf
    Updated Jun 28, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Future Market Insights (2022). HIV Antivirals Market by Product, Distribution Channel & Region - Forecast 2022 - 2032 [Dataset]. https://www.futuremarketinsights.com/reports/hiv-antivirals-market
    Explore at:
    pdfAvailable download formats
    Dataset updated
    Jun 28, 2022
    Dataset authored and provided by
    Future Market Insights
    License

    https://www.futuremarketinsights.com/privacy-policyhttps://www.futuremarketinsights.com/privacy-policy

    Time period covered
    2022 - 2032
    Area covered
    Worldwide
    Description

    [300 Pages Report] The global HIV antivirals market is set to reach a valuation of US$ 30.6 Billion in 2022, and register a CAGR of 4.4% during the forecast period (2022 to 2032). According to a recent study, fixed-dose combinations (FDCs) are leading the HIV antivirals market with a share of over 83% in 2021.

    Market Outlook:

    Data PointsMarket Insights
    HIV Antivirals Market Value 2021US$ 29.4 Billion
    Market Value 2022US$ 30.6 Billion
    Market Value 2032US$ 47.0 Billion
    CAGR 2022 to 20324.4%
    Market Share of Top 5 Countries64.8%

    Report Scope as per HIV Antivirals Market Analysis

    AttributesDetails
    Market Value 2022US$ 30.6 Billion
    Market Value 2032US$ 47.0 Billion
    CAGR 2022-20324.4%
    Forecast Period2017 to 2021
    Historical Data Available for2022 to 2032
    Market AnalysisUS$ Million for Value
    Key Regions CoveredNorth America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
    Key Countries CoveredUSA, China, Japan, Germany, Canada, UK, India, South Korea, Russia, Australia, BENELUX, Spain, Indonesia, France, Italy, Brazil, Thailand, Malaysia, Vietnam, Philippines, Mexico, GCC Countries, Argentina, South Africa, North Africa, Turkey, and New Zealand
    Key Market Segments CoveredProduct, Sales Channel, and Region
    Key Companies Profiled
    • ViiV Healthcare
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Johnson & Johnson
    • Genetech, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie
    • Cipla
    • Pfizer Inc.
    • Mylan N.V.
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH
    • Macleods Pharmaceuticals Ltd
    • Emcure Pharmaceuticals Limited
    • Aspen Pharmacare Limited
    • Lupin Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Theratechnologies Inc.
    • Strides Arcolab Limited
    • Hetero labs limited
    • Laurus Laboratories Ltd
  11. H

    Hiv Drugs Market Report

    • marketreportanalytics.com
    doc, pdf, ppt
    Updated Jun 5, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Report Analytics (2025). Hiv Drugs Market Report [Dataset]. https://www.marketreportanalytics.com/reports/hiv-drugs-market-1374
    Explore at:
    ppt, doc, pdfAvailable download formats
    Dataset updated
    Jun 5, 2025
    Dataset authored and provided by
    Market Report Analytics
    License

    https://www.marketreportanalytics.com/privacy-policyhttps://www.marketreportanalytics.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The size of the Hiv Drugs market was valued at USD XXX billion in 2024 and is projected to reach USD XXX billion by 2033, with an expected CAGR of 5.02% during the forecast period.HIV drugs are those drugs used in the treatment and management of human immunodeficiency virus (HIV) infection. They act by inhibiting the replication of the virus, thus slowing its progression and preventing the spread of the disease. The HIV drugs market comprises a vast number of antiretroviral drugs, such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry inhibitors. These are used in combination regimens for maximum effect and also to reduce the risk of drug resistance.

  12. Maraviroc Market Report | Global Forecast From 2025 To 2033

    • dataintelo.com
    csv, pdf, pptx
    Updated Sep 22, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Dataintelo (2024). Maraviroc Market Report | Global Forecast From 2025 To 2033 [Dataset]. https://dataintelo.com/report/global-maraviroc-market
    Explore at:
    csv, pptx, pdfAvailable download formats
    Dataset updated
    Sep 22, 2024
    Dataset authored and provided by
    Dataintelo
    License

    https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy

    Time period covered
    2024 - 2032
    Area covered
    Global
    Description

    Maraviroc Market Outlook



    The global Maraviroc market size is projected to grow from USD 1.2 billion in 2023 to approximately USD 2.1 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period. The market is driven by various factors, including the rising prevalence of HIV/AIDS, the increasing accessibility of antiretroviral therapies, and the growing awareness about HIV prevention and treatment strategies.



    One of the key growth factors for the Maraviroc market is the escalating incidence of HIV/AIDS globally. According to UNAIDS, approximately 38 million people were living with HIV in 2021, and this number is expected to rise due to factors such as lack of awareness, inadequate healthcare infrastructure, and socio-economic challenges in various regions. The growing burden of HIV/AIDS has necessitated the need for effective antiretroviral therapies like Maraviroc, which is recognized for its efficacy in managing HIV infections. This increasing demand directly contributes to the market's growth.



    In addition to the rising HIV incidence, the improved accessibility and affordability of antiretroviral medications have significantly bolstered the Maraviroc market. Governments and non-governmental organizations (NGOs) have launched numerous initiatives aimed at enhancing the distribution and affordability of HIV medications. For instance, programs like the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria have played pivotal roles in making antiretroviral therapies more accessible to patients in need, thereby driving market growth.



    Furthermore, ongoing advancements in pharmaceutical research and development have led to the introduction of improved formulations and combination therapies that enhance patient compliance and treatment outcomes. Maraviroc, being a CCR5 antagonist, is often combined with other antiretroviral drugs to provide a comprehensive treatment regimen for HIV patients. Such advancements are expected to sustain the market's growth trajectory over the forecast period. Additionally, increasing awareness campaigns and educational programs about HIV prevention and treatment are expected to further propel the market.



    From a regional perspective, North America holds the largest share of the Maraviroc market, largely due to the high prevalence of HIV/AIDS, advanced healthcare infrastructure, and the presence of major pharmaceutical companies. Europe follows closely, driven by substantial healthcare expenditure and government initiatives for HIV treatment. However, the Asia Pacific region is anticipated to exhibit the highest CAGR during the forecast period, attributed to the growing awareness about HIV, increasing healthcare investments, and expanding access to antiretroviral therapies.



    Product Type Analysis



    The Maraviroc market can be segmented by product type into tablets and oral solutions. Tablets dominate the market, owing to factors such as ease of administration, longer shelf life, and patient preference. Tablets are particularly advantageous for chronic conditions like HIV, where long-term medication adherence is crucial. The convenience of tablets makes them a preferred choice among both patients and healthcare providers, thus contributing to their substantial market share.



    Oral solutions, on the other hand, are primarily used for patients with swallowing difficulties, including children and elderly patients. Although this segment holds a smaller share compared to tablets, it plays a vital role in addressing the diverse needs of the patient population. Oral solutions are particularly beneficial in pediatric HIV treatment, where dosing flexibility and ease of administration are critical. The growing focus on pediatric HIV management is expected to drive the demand for oral solutions in the coming years.



    Technological advancements in drug formulation and delivery are also influencing the product type landscape. Pharmaceutical companies are investing in research and development to improve the bioavailability and efficacy of both tablets and oral solutions. Innovations such as extended-release formulations are aimed at reducing dosing frequency and enhancing patient adherence. These advancements are likely to positively impact the growth of both segments.



    Moreover, the regulatory landscape plays a significant role in shaping the product type market. Regulatory approvals for new formulations and the inclusion of Maraviroc in treatment guidelines by health aut

  13. m

    Global Antiretroviral Drug Market Share, Size & Industry Analysis 2033

    • marketresearchintellect.com
    Updated Aug 10, 2020
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Research Intellect (2020). Global Antiretroviral Drug Market Share, Size & Industry Analysis 2033 [Dataset]. https://www.marketresearchintellect.com/product/global-antiretroviral-drug-market-size-and-forcast/
    Explore at:
    Dataset updated
    Aug 10, 2020
    Dataset authored and provided by
    Market Research Intellect
    License

    https://www.marketresearchintellect.com/privacy-policyhttps://www.marketresearchintellect.com/privacy-policy

    Area covered
    Global
    Description

    Get key insights from Market Research Intellect's report_name, valued at current_value in 2024, and forecast to grow to forecast_value by 2033, with a CAGR of cagr_value (2026-2033).

  14. H

    Hiv/Aids Drugs Market Report

    • marketresearchforecast.com
    doc, pdf, ppt
    Updated Jan 20, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Research Forecast (2025). Hiv/Aids Drugs Market Report [Dataset]. https://www.marketresearchforecast.com/reports/hivaids-drugs-market-1010
    Explore at:
    ppt, doc, pdfAvailable download formats
    Dataset updated
    Jan 20, 2025
    Dataset authored and provided by
    Market Research Forecast
    License

    https://www.marketresearchforecast.com/privacy-policyhttps://www.marketresearchforecast.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The Hiv/Aids Drugs Market size was valued at USD 28.79 USD Billion in 2023 and is projected to reach USD 110.60 USD Billion by 2032, exhibiting a CAGR of 21.2 % during the forecast period. HIV/AIDS drugs, known as antiretroviral therapies (ART), are critical in managing and controlling the virus in infected individuals. ART is the use of drugs in combination, which targets the HIV replication in various stages to make its load undetectable and halt its progression to AIDS. HIV medications can be divided into several classes which include NRTIs, NNRTIs, PIs, INSTIs as well as entry inhibitors. Newer trends being adopted in the treatment of HIV disease have been characterized by the combination of two or more drugs in one tablet for compliance and administration of treatment regimens. There are other options of treatment that are newer and that include long-acting injectables and basic combination of two drugs. The existence of HIV/AIDS has impacted the overall health status of the world by increasing the number of people with access to HIV/AIDS drugs and thus reducing the mortality rate among many people. However, there are some challenges that have been associated with their access globally especially in the LICs include, problems of accessibility, issues of drug resistance, and side effects. Key drivers for this market are: Increasing Public Awareness for Safer Medicines to Stimulate Market Value. Potential restraints include: Lack of Access to Treatment and Unawareness of HIV Infection Status May Hinder Growth. Notable trends are: Manufacturers focusing on the Development of Mitral Valve Product will drive the Market .

  15. North America HIV Drugs Market Size, Share, Trends and Forecast by Drug...

    • imarcgroup.com
    pdf,excel,csv,ppt
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    IMARC Group, North America HIV Drugs Market Size, Share, Trends and Forecast by Drug Class, Distribution Channel, and Country, 2025-2033 [Dataset]. https://www.imarcgroup.com/north-america-hiv-drugs-market
    Explore at:
    pdf,excel,csv,pptAvailable download formats
    Dataset provided by
    Imarc Group
    Authors
    IMARC Group
    License

    https://www.imarcgroup.com/privacy-policyhttps://www.imarcgroup.com/privacy-policy

    Time period covered
    2024 - 2032
    Area covered
    North America, Global
    Description

    The North America HIV drugs market size was valued at USD 23.84 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 36.91 Billion by 2033, exhibiting a CAGR of 4.78% from 2025-2033. The market is fueled by rising HIV prevalence, advancements in antiretroviral therapies, and the demand for innovative treatments, particularly focusing on multi-class combinations, drug resistance, and personalized medicine.

    Report Attribute
    Key Statistics
    Base Year
    2024
    Forecast Years
    2025-2033
    Historical Years
    2019-2024
    Market Size in 2024
    USD 23.84 Billion
    Market Forecast in 2033
    USD 36.91 Billion
    Market Growth Rate (2025-2033)4.78%

    IMARC Group provides an analysis of the key trends in each segment of the North America HIV drugs market, along with forecasts at the country and regional levels from 2025-2033. The market has been categorized based on drug class and distribution channel.

  16. c

    HIV Drugs Market Size, Growth, Analysis, Forecast 2024 To 2031

    • consegicbusinessintelligence.com
    pdf,excel,csv,ppt
    Updated Dec 2, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Consegic Business Intelligence Pvt Ltd (2024). HIV Drugs Market Size, Growth, Analysis, Forecast 2024 To 2031 [Dataset]. https://www.consegicbusinessintelligence.com/hiv-drugs-market
    Explore at:
    pdf,excel,csv,pptAvailable download formats
    Dataset updated
    Dec 2, 2024
    Dataset authored and provided by
    Consegic Business Intelligence Pvt Ltd
    License

    https://www.consegicbusinessintelligence.com/privacy-policyhttps://www.consegicbusinessintelligence.com/privacy-policy

    Area covered
    Global
    Description

    The global HIV drugs market size is forecasted to grow with a CAGR of 5.7% between 2024 and 2031, reaching a valuation of USD 52,504.67 million by 2031 from USD 33,807.33 million in 2023.

  17. H

    HIV Drugs Market Report

    • promarketreports.com
    doc, pdf, ppt
    Updated Jun 18, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Pro Market Reports (2025). HIV Drugs Market Report [Dataset]. https://www.promarketreports.com/reports/hiv-drugs-market-6274
    Explore at:
    ppt, doc, pdfAvailable download formats
    Dataset updated
    Jun 18, 2025
    Dataset authored and provided by
    Pro Market Reports
    License

    https://www.promarketreports.com/privacy-policyhttps://www.promarketreports.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The HIV Drugs Market is segmented based on type and end-user. By type, the market is segmented into nucleoside, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, and CCR5 antagonists. By end-user, the market is segmented into hospitals & clinics and specialty centers. Recent developments include: July 2021:To make darunavir paired with ritonavir (DRV/r) as a second-line medication for HIV patients living in low and medium-income countries, Unitaid and Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement with pharmaceutical company Hetero Labs LTD. The price of the deal is US$ 210 per patient/year., March 2021:An agreement for collaboration to co-develop and co-commercialize long-acting HIV medication was made public by Gilead Sciences Inc. and Merck. To create a two-drug HIV treatment regimen, the firms want to combine lenacapavir, an experimental capsid inhibitor from Gilead, with islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor from Merck.. Notable trends are: Growing prevalence of HIV/AIDS is driving the market growth.

  18. m

    HIV Antiretroviral Drug Market Industry Size, Share & Growth Analysis 2033

    • marketresearchintellect.com
    Updated May 15, 2025
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market Research Intellect (2025). HIV Antiretroviral Drug Market Industry Size, Share & Growth Analysis 2033 [Dataset]. https://www.marketresearchintellect.com/product/global-hiv-antiretroviral-drug-market/
    Explore at:
    Dataset updated
    May 15, 2025
    Dataset authored and provided by
    Market Research Intellect
    License

    https://www.marketresearchintellect.com/privacy-policyhttps://www.marketresearchintellect.com/privacy-policy

    Area covered
    Global
    Description

    Explore Market Research Intellect's HIV Antiretroviral Drug Market Report, valued at USD 25.2 billion in 2024, with a projected market growth to USD 35.8 billion by 2033, and a CAGR of 4.8% from 2026 to 2033.

  19. D

    Drugs for HIV Report

    • archivemarketresearch.com
    doc, pdf, ppt
    Updated May 27, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Archive Market Research (2025). Drugs for HIV Report [Dataset]. https://www.archivemarketresearch.com/reports/drugs-for-hiv-347630
    Explore at:
    ppt, doc, pdfAvailable download formats
    Dataset updated
    May 27, 2025
    Dataset authored and provided by
    Archive Market Research
    License

    https://www.archivemarketresearch.com/privacy-policyhttps://www.archivemarketresearch.com/privacy-policy

    Time period covered
    2025 - 2033
    Area covered
    Global
    Variables measured
    Market Size
    Description

    The global market for HIV drugs is a dynamic landscape characterized by significant growth and ongoing evolution. While precise figures for market size and CAGR are not provided, industry reports consistently indicate substantial value. Let's assume, for illustrative purposes, a 2025 market size of $30 billion USD, and a Compound Annual Growth Rate (CAGR) of 5% for the forecast period (2025-2033). This reflects the continued need for effective treatment regimens alongside ongoing research and development efforts to combat drug resistance. Key drivers include the increasing prevalence of HIV globally, particularly in developing nations, alongside continuous improvements in medication efficacy, leading to longer lifespans and better quality of life for those affected. Emerging trends such as the development of long-acting injectable therapies, simplified treatment regimens, and personalized medicine approaches are reshaping the market. However, challenges remain, including the high cost of treatment, access barriers in low- and middle-income countries, and the emergence of drug-resistant strains of HIV. Major pharmaceutical companies like ViiV Healthcare, Gilead Sciences, Merck, and Bristol-Myers Squibb, alongside others, are actively involved in research and development, shaping the competitive landscape. The market's segmentation reflects the variety of available treatment options, including antiretroviral drugs targeting specific viral stages. The projected CAGR of 5% suggests a steady expansion of the HIV drug market over the next decade. This growth is fueled by a combination of factors, including increasing awareness about HIV prevention and treatment, better access to healthcare in some regions, and the continuous innovation in drug development resulting in safer, more effective, and more convenient treatment options. However, the market's evolution isn't solely dependent on growth; it’s also shaped by the ongoing battle against drug resistance, the need for affordable medications in resource-limited settings, and the ongoing efforts of pharmaceutical companies to innovate and gain market share in a competitive sector. This necessitates a multifaceted approach, encompassing both advancements in medicine and solutions for improved access and affordability, to ensure the long-term sustainability and positive impact of the HIV drug market.

  20. Hiv Antiretroviral Therapy Market Report | Global Forecast From 2025 To 2033...

    • dataintelo.com
    csv, pdf, pptx
    Updated Jan 7, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Dataintelo (2025). Hiv Antiretroviral Therapy Market Report | Global Forecast From 2025 To 2033 [Dataset]. https://dataintelo.com/report/hiv-antiretroviral-therapy-market
    Explore at:
    pptx, csv, pdfAvailable download formats
    Dataset updated
    Jan 7, 2025
    Dataset authored and provided by
    Dataintelo
    License

    https://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy

    Time period covered
    2024 - 2032
    Area covered
    Global
    Description

    HIV Antiretroviral Therapy Market Outlook



    The HIV antiretroviral therapy market size was valued at USD 30 billion in 2023 and is projected to reach USD 45 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.5%. This impressive growth can be attributed to several factors, including increasing awareness about HIV, advancements in drug formulations, and the expansion of healthcare infrastructure in developing regions.



    One of the primary growth drivers for the HIV antiretroviral therapy market is the increasing global prevalence of HIV/AIDS. According to the World Health Organization, approximately 37.7 million people were living with HIV worldwide in 2020, and this number is expected to rise if new infections are not curtailed. The growing awareness about the importance of early diagnosis and continuous treatment has led to an increased demand for antiretroviral drugs. Additionally, government initiatives and international funding aimed at combating the HIV epidemic have significantly boosted the market.



    Another factor contributing to the market's growth is the advancement in antiretroviral drug formulations. Modern treatments are more effective, have fewer side effects, and require less frequent dosing compared to earlier drugs. Pharmaceutical companies are investing heavily in research and development to bring forth next-generation antiretroviral therapies, such as long-acting injectables and improved combination therapies. These advancements not only improve patient compliance but also enhance the quality of life for those living with HIV.



    The expansion of healthcare infrastructure, particularly in developing countries, is another significant growth factor. As more regions gain access to better healthcare services and facilities, the diagnosis and treatment rates of HIV/AIDS are expected to rise. Countries in Asia Pacific and Africa are increasingly focusing on strengthening their healthcare systems, which includes improving access to antiretroviral therapy. This, coupled with international support and funding, is likely to drive market growth in these regions.



    From a regional perspective, North America and Europe currently dominate the HIV antiretroviral therapy market, owing to their advanced healthcare systems, higher healthcare expenditure, and robust R&D activities. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by increasing HIV prevalence, improving healthcare infrastructure, and rising awareness about HIV/AIDS. Latin America and the Middle East & Africa are also anticipated to register substantial growth, supported by international aid programs and government initiatives aimed at controlling the HIV epidemic.



    Human Immunodeficiency Virus (HIV) Drugs have been at the forefront of medical research and development, playing a pivotal role in transforming HIV from a fatal disease to a manageable chronic condition. The development of these drugs has been marked by significant milestones, including the introduction of combination therapies that target different stages of the viral life cycle. These therapies have drastically reduced the viral load in patients, improving their quality of life and increasing life expectancy. Continuous innovation in HIV drugs is essential to address the challenges of drug resistance and to enhance treatment efficacy. The market for HIV drugs is expected to grow as new formulations and delivery methods, such as long-acting injectables, are developed to improve patient adherence and outcomes.



    Drug Class Analysis



    The HIV antiretroviral therapy market is segmented based on drug class, including Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry Inhibitors, and others. NRTIs form one of the cornerstone classes of antiretroviral therapy. These drugs work by incorporating themselves into the viral DNA of HIV, preventing the virus from replicating. The widespread use of NRTIs in first-line treatments and their inclusion in combination therapies have significantly bolstered their market share.



    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) also play a crucial role in HIV treatment. Unlike NRTIs, NNRTIs bind directly to the reverse transcriptase enzyme, inhibiting its action and thereby preventing the HIV virus from multiplying. The effectiveness

Share
FacebookFacebook
TwitterTwitter
Email
Click to copy link
Link copied
Close
Cite
Transparency Market Research (2024). HIV Drugs Market [Dataset]. https://www.transparencymarketresearch.com/hiv-drugs-market.html

HIV Drugs Market

Explore at:
7 scholarly articles cite this dataset (View in Google Scholar)
csv, pdfAvailable download formats
Dataset updated
Jun 19, 2024
Dataset authored and provided by
Transparency Market Research
License

https://www.transparencymarketresearch.com/privacy-policy.htmlhttps://www.transparencymarketresearch.com/privacy-policy.html

Time period covered
2024 - 2034
Area covered
Worldwide
Description

  • The global industry was valued at US$ 28.6 Bn in 2023
  • It is expected to grow at a CAGR of 4.7% from 2024 to 2034 and reach US$ 47.5 Bn by the end of 2034

HIV Drugs Market Overview

AttributeDetail
Market Drivers
  • Growing Prevalence of HIV Infections
  • Growing Emphasis on R&D related to HIV Drugs

Regional Analysis

AttributeDetail
Leading RegionNorth America

Global HIV Drugs Market Snapshot

AttributeDetail
Market Size in 2023US$ 28.6 Bn
Market Forecast (Value) in 2034US$ 47.5 Bn
Growth Rate (CAGR)4.7%
Forecast Period2024-2034
Historical Data Available for2020-2022
Quantitative UnitsUS$ Bn for Value
Market AnalysisIt includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2023)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
FormatElectronic (PDF) + Excel
Market Segmentation
  • Drug Type
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Fusion Inhibitors (FIs)
    • C-C Chemokine Receptor Type 5 (CCR5)
    • Integrase Inhibitors
    • Attachment Inhibitors
    • Post Attachment Inhibitors
    • Pharmacokinetic Enhancers
    • Post-Exposure Prophylaxis (PEP)
    • Pre-Exposure Prophylaxis (PrEP)
    • Others (Combination HIV Medications, etc.)
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GSK plc
  • AbbVie Inc.
  • Cipla Limited
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
Customization ScopeAvailable Upon Request
PricingAvailable Upon Request

Search
Clear search
Close search
Google apps
Main menu